Pune-based Emcure Pharmaceuticals has pulled out its proposed red herring prospectus or DRHP with securities market regulator SEBI. Emcure Pharmaceuticals on Wednesday said it has filed a draft red herring prospectus (DRHP) with the Sebi for launching an initial public offer. Pune-based Emcure Pharmaceuticals has filed draft red herring prospectus ( DRHP) with SEBI for initial public offering that includes fresh issue.
|Published (Last):||25 June 2009|
|PDF File Size:||9.69 Mb|
|ePub File Size:||14.3 Mb|
|Price:||Free* [*Free Regsitration Required]|
Emcure Pharmaceuticals withdraws proposed IPO | VCCircle
By Jasleen Kaur Batra. Another pharmaceutical firm which filed for public offering recently was Intas Pharmaceuticals. It has subsidiaries in Brazil, DubaiNigeria, Singapore and South Africa and branch offices in Morocco and Russiawhich play an important role in its international operations, the release said.
Crude oil prices to direct sugar prices in Emcure Pharmaceuticals acquires Canadian company and its marketing arm Marcan. Fortis again pushes back date to complete RHT Dhrp deal; auditor resigns.
The Thomson Reuters Trust Principles. Emcure is ranked among the top 15 pharmaceutical companies in India in terms of market share based on the domestic sales of pharmaceutical products. Choose your reason below and click on the Report button. Find this comment offensive? Interestingly, all the firms which decided not to go ahead with public floats are backed by private equity investors.
Emckre is an infrastructure development company which operates in road, irrigation, real estate and hydro power projects.
We have not given a thought to a pre-IPO funding round.
Emcure Pharmaceuticals files IPO papers with SEBI –
Thu, Dec 19 From Berlin to Washington: Here’s how the world is celebrating Christmas. For the nine months ended December 31,Emcure’s revenue from operations was Rs 1, crore with net profit at Rs Emcure operates nine manufacturing facilities, eight of which are located in India and one in the United States. Book running lead managers to the issue include Bank of America Merrill Lynch. The transaction is subject to conditions under contract and law including Foreign Investment Promotion Board approval.
The company commercialises its products through a combination of its own marketing and distribution infrastructure. My Saved Articles Sign in Sign up.
Emcure Pharmaceuticals files for IPO; Blackstone to part exit
Ltd with returns of almost three times. Emcure Pharmaceuticals withdraws proposed IPO. To see your saved stories, click on link hightlighted in bold. Antibiotics made by Emcure Pharmaceuticals recalled in US. Blackstone Emcure Bain Capital private equity stake. Log in Keep me signed in.
Reliance to buy majority stake in renewable energy services firm Kanoda. Emcure is ranked the 14th largest pharmaceutical company in India in terms of market share based on the domestic sales of pharmaceutical products, according to healthcare services information provider IMS Health India.
Fill in your details: The company is engaged in developing, manufacturing and marketing a broad range of pharmaceutical products globally.
Link Intime India Private Limited is a registrar to the issue. Pune-based Emcure Pharmaceuticals has pulled out its proposed initial public offer IPO which was to raise around Rs crore besides giving part exit to Blackstone in its maiden investment in India.
Read more on Emcure Pharmaceuticals. Emcure is a fast growing Indian pharmaceutical company engaged in developing, manufacturing and marketing a broad range of pharmaceutical products globally. It is ranked much higher in the therapeutic areas in which it operates.
Drag according to your convenience. Fri, Dec 20 Emcure is ranked as the 14th-largest pharmaceutical company in India in terms of market share based on the domestic sales of pharmaceutical products.
The issue also involves a secondary sale 2. Pune-based Emcure Pharmaceuticals has filed draft red herring prospectus DRHP with SEBI for initial public offering that includes fresh issue of upto Rs crore and an offer for sale of upto 25,13, equity share.
Bain Capital has paid nearly Rs. Promoter Satish Ramanlal Mehta holds This will alert our moderators to take action. This will alert our moderators to take action Name Reason for reporting: Sensex finishes year above 36, posts third straight annual gain. Deepti Chaudhary Malvika Joshi.
NIFTY 50 10, 2. The pharma company intends to utilise the net proceeds for setting up of new manufacturing facilities and expansion of existing manufacturing facilities; research and development; and general corporate purposes.
Secondary transactions vrhp the ground for appropriate valuations as there is no information arbitrage unlike in ekcure primary transaction. Mandhana added that while an IPO is a convenient route for exits, secondary transactions provide more comfort to the new investor as potential corporate governance issues would have already been taken care of by the exiting PE firm.
British support-services provider Serco Group Plc. This follows a deal struck late last year where Blackstone sold its stake to Bain Capital for an undisclosed amount.